AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14676530 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic assessment for fixator removal
Number of subjects: 42
Study 10878147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative sports-exercise scores between ages 12 and 18 years
Number of subjects: 81
Study 10878147 — intervention group
Group type: EXPERIMENTAL
Intervention: Time‐averaged daily calcium intake (500 to 1500 mg/day)
Number of subjects: 81
Study 9132715 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 40
Study 9132715 — intervention group
Group type: COMPARATOR
Intervention: Games
Number of subjects: 40
Study 9132715 — intervention group
Group type: COMPARATOR
Intervention: School group
Number of subjects: 40
Study 9132715 — intervention group
Group type: EXPERIMENTAL
Intervention: Home group
Number of subjects: 40
Study 8410764 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype filament suspension design toothbrush (active suspension)
Number of subjects: 0
Study 8410764 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype filament suspension design toothbrush (inactive suspension)
Number of subjects: 0
Study 8410764 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrush
Number of subjects: 0
Study 3516668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavior Therapy
Number of subjects: 27
Study 3516668 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Counseling
Number of subjects: 27
Study 3516668 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 27
Study 30243867 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional group (group 2) - toys and video games for children, counseling and information for parents
Number of subjects: 60
Study 30243867 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1) - noninterventional
Number of subjects: 60
Study 30243867 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional group (group 2)
Number of subjects: 60
Study 28275117 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsatuzumab (400 mg) in combination with mFOLFOX6 plus bevacizumab (5 mg/kg)
Number of subjects: 127
Study 28275117 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with mFOLFOX6 plus bevacizumab (5 mg/kg)
Number of subjects: 127
Study 25264670 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Resistance Training (HRT): 4 × 10 repetitions, 70-80% one repetition maximum (1RM)
Number of subjects: 23
Study 25264670 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Resistance Training with Blood Flow Restriction (LRT-BFR): 4 sets (1 × 30 and 3 × 15 repetitions), 20-30% 1RM
Number of subjects: 23
Study 23726657 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy with or without tonsillectomy
Number of subjects: 35
Study 23726657 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (no adenotonsillar disease)
Number of subjects: 35
Study 22180731 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilation
Number of subjects: 1300
Study 22180731 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1300
Study 18222671 — intervention group
Group type: EXPERIMENTAL
Intervention: Aescin and troxerutin combination treatment
Number of subjects: 68
Study 18222671 — intervention group
Group type: COMPARATOR
Intervention: Pentoxyfyllin
Number of subjects: 68
Study 16838478 — intervention group
Group type: EXPERIMENTAL
Intervention: One-Step Plus (phosphoric acid conditioner)
Number of subjects: 28
Study 16838478 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (self-etching primer)
Number of subjects: 28
Study 16838478 — intervention group
Group type: COMPARATOR
Intervention: Comparison of One-Step Plus and Clearfil SE Bond
Number of subjects: 28
Study 12725561 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of SHR-5 Rhodiola rosea extract (2 capsules)
Number of subjects: 161
Study 12725561 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of SHR-5 Rhodiola rosea extract (3 capsules)
Number of subjects: 161
Study 12725561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 11089761 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ET(A) receptor antagonist (LU‐135252, 3 mg/kg, inhaled over 1 h)
Number of subjects: 16
Study 11089761 — intervention group
Group type: COMPARATOR
Intervention: Nebulization of saline (5-10 ml inhaled over 1 h)
Number of subjects: 16
Study 9158351 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 0.75% bupivacaine and general anesthesia (n = 6)
Number of subjects: 12
Study 9158351 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with thiopentone, vecuronium, fentanyl, or enflurane (control group, n = 6)
Number of subjects: 12
Study 8093824 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol acetate
Number of subjects: 143
Study 8093824 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 143
Study 8093824 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol
Number of subjects: 143
Study 8093824 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Zuclopenthixol acetate, Haloperidol, Zuclopenthixol)
Number of subjects: 143
Study 3690045 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (16 to 20 g)
Number of subjects: 17
Study 29513635 — intervention group
Group type: EXPERIMENTAL
Intervention: Strip-type bleaching agent
Number of subjects: 75
Study 29513635 — intervention group
Group type: EXPERIMENTAL
Intervention: Paint-on-type bleaching agent
Number of subjects: 75
Study 29513635 — intervention group
Group type: COMPARATOR
Intervention: Negative control (products without H2O2)
Number of subjects: 75
Study 29513635 — intervention group
Group type: COMPARATOR
Intervention: Positive control (dentist-supervised home bleaching)
Number of subjects: 75
Study 29513635 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (strip, paint-on, and controls)
Number of subjects: 75
Study 28682707 — intervention group
Group type: EXPERIMENTAL
Intervention: VAMOS group (behavior change program)
Number of subjects: 90
Study 28682707 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 25636028 — intervention group
Group type: EXPERIMENTAL
Intervention: Sticky mittens
Number of subjects: 24
Study 25636028 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sticky mittens
Number of subjects: 24
Study 25636028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study 24122257 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus CIK
Number of subjects: 58
Study 24122257 — intervention group
Group type: COMPARATOR
Intervention: S-1 alone (CT group)
Number of subjects: 58
Study 20543751 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomaltulose (ISO), 75 g, GI = 32
Number of subjects: 8
Study 19032300 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 microg
Number of subjects: 204
Study 19032300 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine 10 mg
Number of subjects: 204
Study 17138192 — intervention group
Group type: EXPERIMENTAL
Intervention: IA morphine 5 mg
Number of subjects: 60
Study 17138192 — intervention group
Group type: COMPARATOR
Intervention: IA saline 1 mL (placebo)
Number of subjects: 60
Study 12721242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP)
Number of subjects: 0
Study 12721242 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 0
Study 12721242 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and cisplatin (CP)
Number of subjects: 0
Study 10848717 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (specific agents not mentioned)
Number of subjects: 0
Study 10848717 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II and III clinical trial programme (specific agents not mentioned)
Number of subjects: 0
Study 7758059 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac dispersible 50 mg three times daily for 3 to 7 days
Number of subjects: 253
Study 7758059 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac dispersible 50 mg
Number of subjects: 253
Study 7758059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 2204776 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (250 mg b.i.d.)
Number of subjects: 20
Study 2204776 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (30 mg b.i.d.)
Number of subjects: 20
Study 386697 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumide (1200 mg/day)
Number of subjects: 16
Study 386697 — intervention group
Group type: COMPARATOR
Intervention: Magnesium trisilicate (1320 mg/day)
Number of subjects: 16
Study 386697 — intervention group
Group type: COMPARATOR
Intervention: Proglumide (1200 mg/day) and Magnesium trisilicate (1320 mg/day)
Number of subjects: 16
Study 29596662 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakout items for each product (B)
Number of subjects: 4100
Study 29596662 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakout items for each product with images (B + I)
Number of subjects: 4100
Study 29596662 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist and breakout items (CL and B)
Number of subjects: 4100
Study 29596662 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist and breakout items with images (CL and B + I)
Number of subjects: 4100
Study 29596662 — intervention group
Group type: COMPARATOR
Intervention: Checklist (CL)
Number of subjects: 4100
Study 27925466 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration iodinated contrast agent (270 mgI/ml) and low tube current (120 mA)
Number of subjects: 110
Study 27925466 — intervention group
Group type: COMPARATOR
Intervention: Standard dose protocol (370 mgI/ml) and conventional tube current (160 mA)
Number of subjects: 110
Study 26079777 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative Tight Glucose Control (TGC)
Number of subjects: 2383
Study 26079777 — intervention group
Group type: COMPARATOR
Intervention: Postoperative Tight Glucose Control (TGC)
Number of subjects: 2383
Study 26079777 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative TGC in nondiabetic subjects
Number of subjects: 2383
Study 26079777 — intervention group
Group type: COMPARATOR
Intervention: Postoperative TGC in nondiabetic subjects
Number of subjects: 2383
Study 26079777 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative TGC in diabetic patients
Number of subjects: 2383
Study 24335524 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea cucumber jelly (containing hydrolysate of Stichopus japonicus)
Number of subjects: 17
Study 24335524 — intervention group
Group type: COMPARATOR
Intervention: Control jelly (without S. japonicus)
Number of subjects: 17
Study 21143588 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information brochure on improving vitamin D status in native language
Number of subjects: 44
Study 21143588 — intervention group
Group type: COMPARATOR
Intervention: Usual care (oral information only)
Number of subjects: 44
Study 21143588 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intervention and control groups
Number of subjects: 44
Study 19041012 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive thyroid surgery (MITS) through a lateral 2.5-cm incision
Number of subjects: 100
Study 19041012 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemithyroidectomy (CHT) through a traditional 5- to 6-cm cervicotomy
Number of subjects: 100
Study 16433875 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIDFORM gel (5 g, intravaginally once daily for five consecutive days)
Number of subjects: 30
Study 16433875 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole gel (10%, intravaginally once daily for five consecutive days)
Number of subjects: 30
Study 16433875 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIDFORM gel
Number of subjects: 30
Study 16433875 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole gel
Number of subjects: 30
Study 14506625 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IGF-I (15 microg/kg body weight/d twice daily)
Number of subjects: 24
Study 14506625 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 10981173 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose spironolactone
Number of subjects: 0
Study 10981173 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective aldosterone antagonists
Number of subjects: 0
Study 9298392 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 200
Study 9298392 — intervention group
Group type: COMPARATOR
Intervention: Small‐incision cholecystectomy
Number of subjects: 200
Study 8509754 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% prilocaine
Number of subjects: 30
Study 8509754 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% mepivacaine
Number of subjects: 30
Study 8509754 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine (1:100,000 epinephrine)
Number of subjects: 30
Study 3119520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost sharing
Number of subjects: 3565
Study 3119520 — intervention group
Group type: COMPARATOR
Intervention: Free care
Number of subjects: 3565
Study 29035687 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (GLN)
Number of subjects: 13
Study 29035687 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13
Study 27542384 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fruit at work intervention for 18 weeks
Number of subjects: 23
Study 25080462 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant human growth hormone (rhGH) (0.05 mg · kg⁻¹ · d⁻¹)
Number of subjects: 8
Study 25080462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 22722511 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-enriched air inhalation (normobaric hyperoxia of 40% fraction of inspired oxygen)
Number of subjects: 20
Study 22722511 — intervention group
Group type: COMPARATOR
Intervention: Regular air inhalation (21% fraction of inspired oxygen)
Number of subjects: 20
Study 22722511 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-enriched air inhalation
Number of subjects: 20
Study 22722511 — intervention group
Group type: COMPARATOR
Intervention: Regular air inhalation
Number of subjects: 20
Study 20398563 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (5 g/d intravenously for seven days)
Number of subjects: 66
Study 18779465 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-specific personal health record (PHR) that imported clinical and medications data, provided patient-tailored decision support, and enabled the patient to author a 'Diabetes Care Plan' for electronic submission to their physician.
Number of subjects: 244
Study 18779465 — intervention group
Group type: COMPARATOR
Intervention: Active control PHR to update and submit family history and health maintenance information.
Number of subjects: 244
Study 18779465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups after 1 year.
Number of subjects: 244
Study 15625373 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 561
Study 15625373 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-paclitaxel combination
Number of subjects: 561
Study 15625373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy in performance status 2 patients
Number of subjects: 561
Study 12027065 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (60 mg, twice daily)
Number of subjects: 0
Study 12027065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12027065 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal antigen challenge
Number of subjects: 0
Study 10690141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg i.v.
Number of subjects: 90
Study 10690141 — intervention group
Group type: COMPARATOR
Intervention: Saline 2 ml i.v. (Control)
Number of subjects: 90
Study 8542136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan (HA) for 6 months
Number of subjects: 29
Study 8542136 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 months
Number of subjects: 29
Study 1450310 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.1 cc/kg) administered to Group 1 (G1) patients 3 minutes prior to intubation
Number of subjects: 20
Study 1450310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg/kg) administered to Group 2 (G2) patients 3 minutes prior to intubation
Number of subjects: 20
Study 6375621 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 60
Study 6375621 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 60
Study 6375621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30823963 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance interval training
Number of subjects: 26
Study 30823963 — intervention group
Group type: COMPARATOR
Intervention: Aerobic interval training alone
Number of subjects: 26
Study 30261986 — intervention group
Group type: EXPERIMENTAL
Intervention: Single educational session by a respiratory nurse specialist for about 10 minutes
Number of subjects: 160
Study 30261986 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational session)
Number of subjects: 160
Study 27214664 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipraglurant (50 mg once daily)
Number of subjects: 76
Study 27214664 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipraglurant (100 mg 3 times daily)
Number of subjects: 76
Study 27214664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 26037427 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based early goal-directed therapy (EGDT)
Number of subjects: 1341
Study 26037427 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-based standard therapy (ST)
Number of subjects: 1341
Study 26037427 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1341
Study 22786751 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan 10 mg/day
Number of subjects: 594
Study 22786751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study 20142025 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived adverse effects (AE) such as dizziness, dry cough, nausea, diarrhea, and gout.
Number of subjects: 754
Study 20142025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry cough (perceived AE).
Number of subjects: 754
Study 20142025 — intervention group
Group type: EXPERIMENTAL
Intervention: Gout (perceived AE).
Number of subjects: 754
Study 18678157 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Valpromide
Number of subjects: 60
Study 18678157 — intervention group
Group type: COMPARATOR
Intervention: Valpromide (medication group)
Number of subjects: 60
Study 15944531 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole-stress imaging
Number of subjects: 92
Study 15944531 — intervention group
Group type: COMPARATOR
Intervention: Redistribution images
Number of subjects: 92
Study 12463967 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment for 6 months until normalization of TSH
Number of subjects: 31
Study 12463967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 10472236 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine gel 1 g applied for 45 min
Number of subjects: 60
Study 10472236 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream 2 g applied for 60 min
Number of subjects: 60
Study 9121999 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxin treatment
Number of subjects: 12
Study 9121999 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 12
Study 1830636 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol valerate combined with cyproterone acetate, medroxyprogesterone acetate or levonorgestrel
Number of subjects: 148
Study 1830636 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg 17 beta‐oestradiol combined with desogestrel
Number of subjects: 148
Study 1830636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 1830636 — intervention group
Group type: EXPERIMENTAL
Intervention: All hormone regimens
Number of subjects: 148
Study 1830636 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone derivatives
Number of subjects: 148
Study 7258218 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (2 ml/kg of body weight)
Number of subjects: 20
Study 7258218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7258218 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after alcohol ingestion)
Number of subjects: 20
Study 31460835 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% Chlorhexidine Gluconate (CHG)
Number of subjects: 267
Study 31460835 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 267
Study 31462284 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based financing and integrated care intervention
Number of subjects: 1084
Study 31462284 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 1084
Study 28364685 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one peer support delivered by trained peers over six months
Number of subjects: 216
Study 28364685 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 216
Study 26991724 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily isometric hand grip exercises before chemotherapy
Number of subjects: 0
Study 26991724 — intervention group
Group type: COMPARATOR
Intervention: Routine activities only (Control)
Number of subjects: 0
Study 26991724 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily isometric hand grip exercises
Number of subjects: 0
Study 24692089 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 19481
Study 24692089 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (OP)
Number of subjects: 19481
Study 22116959 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal VEP amplitudes
Number of subjects: 58